Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PU-PEI-miR145
- Development stage
- Preclinical
- Lead developer
- National Yang-Ming University
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intratumoral
01
Overview
PU-PEI-miR145 is an experimental, nonviral microRNA delivery therapeutic consisting of tumor-suppressive miR-145 complexed with a cationic polyurethane-short branch polyethylenimine carrier. In glioblastoma CD133-positive cancer stem-like cells, delivered miR-145 directly suppresses the stemness-associated transcription factors OCT4 and SOX2, reducing tumorigenic and cancer stem-like properties, promoting differentiation, and increasing sensitivity to radiotherapy and temozolomide. Preclinical local intracranial administration suppressed orthotopic glioblastoma tumorigenesis and improved survival in immunocompromised mouse models. ([aacrjournals.org](https://aacrjournals.org/cancerres/article/72/8_Supplement/3332/580191/Abstract-3332-Inhibition-of-cancer-stem-like))
- Other names
- PU-PEI-miR145PU-PEI-miR-145PU-PEI-miR 145
02
Targets
Kruppel-like factor 4 (KLF4) mRNAPOU domain class 5 transcription factor 1 mRNA (POU5F1 mRNA)SRY-box transcription factor 2 mRNA (SOX2 mRNA)PAI-1 (Plasminogen activator inhibitor type 1)
Beyond the preview
Go deeper on PU-PEI-miR145.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PU-PEI-miR145.